Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

作者：Matthew Ryan Smith, Josep M. Piulats, Tilman Todenhöfer, Jae‐Lyun Lee, Jóse Ángel Arranz Arija, Laura Mazilu, Arun Azad, Teresa Alonso‐Gordoa, Ursula McGovern, Atish D. Choudhury, Lisa G. Horvath, Dingwei Ye, Weiqing Han, Hiroyoshi Suzuki, Hiroji Uemura, Rana R. McKay, Steven Ades, Aude Fléchon, Christopher Pieczonka, Mariana Fernandes, Maarten Hulstijn, Andrew Lithio, Karim Nacerddine, Neeraj Agarwal · 发表于：The Lancet Oncology · 年份：2025 · DOI：10.1016/s1470-2045(25)00475-9 · 被引用次数：3 · 研究领域：Advanced Breast Cancer Therapies、Prostate Cancer Treatment and Research、Lung Cancer Research Studies